BEAM ▲ +3.7% - Beam Therapeutics Inc. $BEAM Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Beam Therapeutics rose 3.7% following the release of updated clinical data from its Phase 1/2 trial of BEAM-302, a gene-editing therapy for alpha-1 antitrypsin deficiency. Positive clinical progress in early-stage trials typically encourages investor optimism about a candidate's potential path toward commercialization. 08-SEP-2026 06:11 AM ET